Annex VI: Implementation of mandatory VNeeS format for Veterinary regulatory submissions <> "Error*"Annex VI: Implementation of mandatory VNeeS format for Veterinary regulatory submissions \* MERGEFORMAT Annex VI: Imple

First Page		Document Content
Date: 2016-08-19 03:16:08 Pharmaceutical industry Medical research Clinical data management Clinical research Health care Evaluation Validity Quality Validation Marketing authorization Electronic submission		Annex VI: Implementation of mandatory VNeeS format for Veterinary regulatory submissions <> "Error"Annex VI: Implementation of mandatory VNeeS format for Veterinary regulatory submissions \ MERGEFORMAT Annex VI: Imple Add to Reading List Source URL: esubmission.ema.europa.eu Download Document from Source Website File Size: 174,50 KB Share Document on Facebook

	TIGes vet Q&A-update - Sept 2013 DocID: 1rsZK - View Document
	BPGWorksharingEMA-CMDv DocID: 1rr9m - View Document
	CMDh meeting with representative of Interested Parties 19 May 2015  Type IA variation label implementation guidance. DocID: 1rqES - View Document
	Annex VI: Implementation of mandatory VNeeS format for Veterinary regulatory submissions <> "Error"Annex VI: Implementation of mandatory VNeeS format for Veterinary regulatory submissions \ MERGEFORMAT Annex VI: Imple DocID: 1rqtS - View Document
	Quasi Drug Rules in Japan December 2011 Quasi-drugs are a unique product classification in Japan. A quasi-drug is defined in Japan as products that have minimal to moderate pharmacologic activity but are restricted in us DocID: 1rpxR - View Document